Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2007 1
2011 1
2012 2
2013 3
2014 3
2015 9
2016 14
2017 20
2018 24
2019 36
2020 53
2021 82
2022 102
2023 93
2024 50

Text availability

Article attribute

Article type

Publication date

Search Results

423 results

Results by year

Filters applied: . Clear all
Page 1
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.
Molina JM, Rizzardini G, Orrell C, Afani A, Calmy A, Oka S, Hinestrosa F, Kumar P, Tebas P, Walmsley S, Grandhi A, Klopfer S, Gendrano I, Eves K, Correll TA, Fox MC, Kim J. Molina JM, et al. Lancet HIV. 2024 May 8:S2352-3018(24)00031-6. doi: 10.1016/S2352-3018(24)00031-6. Online ahead of print. Lancet HIV. 2024. PMID: 38734015
INTERPRETATION: Switching to single-tablet doravirine (100 mg) and islatravir (0.75 mg) maintained viral suppression up to week 48 and was non-inferior to antiretroviral combinations used in clinical practice for adults with HIV-1; however, decreases in CD4 cell and total lymphoc …
INTERPRETATION: Switching to single-tablet doravirine (100 mg) and islatravir (0.75 mg) maintained viral suppression up to week 48 and was n …
Accelerating Progress Towards the 2030 Neglected Tropical Diseases Targets: How Can Quantitative Modeling Support Programmatic Decisions?
Vasconcelos A, King JD, Nunes-Alves C, Anderson R, Argaw D, Basáñez MG, Bilal S, Blok DJ, Blumberg S, Borlase A, Brady OJ, Browning R, Chitnis N, Coffeng LE, Crowley EH, Cucunubá ZM, Cummings DAT, Davis CN, Davis EL, Dixon M, Dobson A, Dyson L, French M, Fronterre C, Giorgi E, Huang CI, Jain S, James A, Kim SH, Kura K, Lucianez A, Marks M, Mbabazi PS, Medley GF, Michael E, Montresor A, Mutono N, Mwangi TS, Rock KS, Saboyá-Díaz MI, Sasanami M, Schwehm M, Spencer SEF, Srivathsan A, Stawski RS, Stolk WA, Sutherland SA, Tchuenté LT, de Vlas SJ, Walker M, Brooker SJ, Hollingsworth TD, Solomon AW, Fall IS. Vasconcelos A, et al. Clin Infect Dis. 2024 Apr 25;78(Supplement_2):S83-S92. doi: 10.1093/cid/ciae082. Clin Infect Dis. 2024. PMID: 38662692 Free PMC article.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
CONCLUSIONS: Adjuvant pembrolizumab was associated with a significant and clinically meaningful improvement in overall survival, as compared with placebo, among participants with clear-cell renal-cell carcinoma at increased risk for recurrence after surgery. (Funded by Merck Shar …
CONCLUSIONS: Adjuvant pembrolizumab was associated with a significant and clinically meaningful improvement in overall survival, as compared …
Remote Monitoring and Data Collection for Decentralized Clinical Trials.
Daly B, Brawley OW, Gospodarowicz MK, Olopade OI, Fashoyin-Aje L, Smart VW, Chang IF, Tendler CL, Kim G, Fuchs CS, Beg MS, Zhang L, Legos JJ, Duran CO, Kalidas C, Qian J, Finnegan J, Pilarski P, Keane H, Shen J, Silverstein A, Wu YL, Pazdur R, Li BT. Daly B, et al. JAMA Netw Open. 2024 Apr 1;7(4):e246228. doi: 10.1001/jamanetworkopen.2024.6228. JAMA Netw Open. 2024. PMID: 38607626 Free PMC article.
Transoral Robotic Surgery and Radiation Volume Deintensification in Unknown Primary Squamous Cell Carcinoma of the Neck: The Phase 2 FIND Nonrandomized Controlled Trial.
de Almeida JR, Martino R, Hosni A, Goldstein DP, Bratman SV, Chepeha DB, Waldron JN, Weinreb I, Perez-Ordonez B, Yu E, Metser U, Hansen AR, Xu W, Su SJ, Kim J. de Almeida JR, et al. JAMA Otolaryngol Head Neck Surg. 2024 Apr 11:e240423. doi: 10.1001/jamaoto.2024.0423. Online ahead of print. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38602692
Clinical Workflow of Cone Beam Computer Tomography-Based Daily Online Adaptive Radiotherapy with Offline Magnetic Resonance Guidance: The Modular Adaptive Radiotherapy System (MARS).
Kim JY, Tawk B, Knoll M, Hoegen-Saßmannshausen P, Liermann J, Huber PE, Lifferth M, Lang C, Häring P, Gnirs R, Jäkel O, Schlemmer HP, Debus J, Hörner-Rieber J, Weykamp F. Kim JY, et al. Cancers (Basel). 2024 Mar 19;16(6):1210. doi: 10.3390/cancers16061210. Cancers (Basel). 2024. PMID: 38539544 Free PMC article.
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Ferrante M, Jordi Guardiola, Jahnsen J, Louis E, Lukáš M, Reinisch W, Roblin X, Smith PJ, Kwon T, Kim J, Yoon S, Kim DH, Atreya R. Peyrin-Biroulet L, et al. BMC Gastroenterol. 2024 Mar 27;24(1):121. doi: 10.1186/s12876-024-03163-5. BMC Gastroenterol. 2024. PMID: 38539103 Free PMC article.
The International Association for the Study of Lung Cancer (IASLC) Staging Project for Lung Cancer: Recommendation to Introduce Spread Through Air Spaces as a Histologic Descriptor in the Ninth Edition of the TNM Classification of Lung Cancer. Analysis of 4061 Pathologic Stage I NSCLC.
Travis WD, Eisele M, Nishimura KK, Aly RG, Bertoglio P, Chou TY, Detterbeck FC, Donnington J, Fang W, Joubert P, Kernstine K, Kim YT, Lievens Y, Liu H, Lyons G, Mino-Kenudson M, Nicholson AG, Papotti M, Rami-Porta R, Rusch V, Sakai S, Ugalde P, Van Schil P, Yang CJ, Cilento VJ, Yotsukura M, Asamura H; Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Members of the Advisory Boards, and Participating Institutions of the Lung Cancer Domain. Travis WD, et al. J Thorac Oncol. 2024 Mar 18:S1556-0864(24)00122-9. doi: 10.1016/j.jtho.2024.03.015. Online ahead of print. J Thorac Oncol. 2024. PMID: 38508515
423 results